FDAnews Drug Daily Bulletin

WESTAIM'S NUCRYST PHARMACEUTICAL UNIT PLANS INITIAL PUBLIC OFFERING

Nov. 7, 2005
A A

The Westaim Corporation, which has been nurturing two emerging businesses, said Wednesday that its Nucryst Pharmaceuticals subsidiary is planning its initial public offering to fund its operations. Westaim said it would not sell any of its Nucryst shares and expected to retain control of the company after an unspecified portion of the company is sold to public markets within the next six months.

Canada.com (http://www.canada.com/health/story.html?id=c7b2f301-cdc3-4813-b274-23729e088077)